Evidence map›Paper›PMID 42103721›Full record

ArticleNature communications2026

Maternal RSV vaccination generates high-affinity antibodies that efficiently transfer to infants, providing enhanced passive immunity.

Dongxiao Liu, Olivia Posadas, Ashish K Mishra, Mohamed M Mire, Mindy Pike, Janet A Englund, Alisa Kachikis, Surender Khurana

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Dongxiao Liu *Division of Viral Products, Center for Biologics Evaluation and Research (CBER), FDA, Silver Spring, MD, USA.ORCID http://orcid.org/0000-0001-9656-8976
Olivia Posadas *Division of Viral Products, Center for Biologics Evaluation and Research (CBER), FDA, Silver Spring, MD, USA.
Ashish K Mishra *Division of Viral Products, Center for Biologics Evaluation and Research (CBER), FDA, Silver Spring, MD, USA.
Mohamed M MireDivision of Viral Products, Center for Biologics Evaluation and Research (CBER), FDA, Silver Spring, MD, USA.
Mindy PikeDepartment of Obstetrics and Gynecology, University of Washington, Seattle, WA, USA.
Janet A EnglundDepartment of Pediatrics, University of Washington, and Seattle Children's Research Institute, Seattle, WA, USA.ORCID http://orcid.org/0000-0003-1134-4178
Alisa KachikisDepartment of Obstetrics and Gynecology, University of Washington, Seattle, WA, USA.
Surender KhuranaDivision of Viral Products, Center for Biologics Evaluation and Research (CBER), FDA, Silver Spring, MD, USA. Surender.Khurana@fda.hhs.gov.ORCID http://orcid.org/0000-0002-0593-7965

Funding

Transform Dissemination and Implementation Science in CTSA ProgramsUL1TR002319 · NCATS · UNIVERSITY OF WASHINGTON · PI John K. Amory · 2017 to 2026
$100.0M
Protection of at-risk low birth weight infants against influenza via maternal antibodyK23AI153390 · NIAID · UNIVERSITY OF WASHINGTON · PI KACHIKIS, ALISA · 2021 to 2025
$942k
NCATS NIH HHS UL1 TR002319NIAID NIH HHS K23 AI153390U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID) K23AI153390U.S. Department of Health & Human Services | U.S. Food and Drug Administration (U.S. Food & Drug Administration) Intramural funding
6 · The paper itself

Abstract

Respiratory syncytial virus (RSV) remains the leading cause of hospitalization in young children. A bivalent pre-fusion (preF) protein RSV vaccine was licensed for pregnant persons in 2023 (Abrysvo, Pfizer), but the impact of RSV maternal immunization on maternal-fetal immunity has not been well characterized. We analyze neutralizing antibody responses, binding antibodies, and antibody affinity maturation in 58 unvaccinated and 49 vaccinated pregnant individuals and their infants. Maternal RSV vaccination induces robust neutralizing antibodies against both RSV-A2 and RSV-B1 strains, with geometric mean titers 8-fold and 13.4-fold higher, respectively, in vaccinated versus unvaccinated participants. Vaccination significantly enhances binding antibodies to RSV-preF protein (5.2-fold higher) and antibody affinity maturation (3.7-fold higher). High-quality RSV-specific antibodies are efficiently transferred across the placenta. However, early preterm infants showed reduced antibody transfer efficiency compared with full-term infants. These findings demonstrate that maternal RSV vaccination generates high-quality, affinity-matured transferable antibodies that provide passive immunity to infants.

Indexed as

Antibodies, ViralImmunity, Maternally-AcquiredRespiratory Syncytial Virus, HumanRespiratory Syncytial Virus InfectionsRespiratory Syncytial Virus VaccinesAdultAntibodies, NeutralizingAntibody AffinityFemaleHumansInfantInfant, NewbornPregnancyVaccinationAntibodies, NeutralizingAntibodies, ViralRespiratory Syncytial Virus Vaccines

Identifiers

PMID42103721
PMCPMC13369169

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.